Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Proton pump inhibitors and gastric cancer: association is not causation.

Moayyedi P, Veldhuyzen van Zanten SJO, Hookey L, Armstrong D, Jones N, Leontiadis GI.

Gut. 2019 Aug;68(8):1529-1530. doi: 10.1136/gutjnl-2018-316958. Epub 2018 Jul 13. No abstract available.

PMID:
30006494
2.

Variable Quality and Readability of Patient-oriented Websites on Colorectal Cancer Screening.

Schreuders EH, Grobbee EJ, Kuipers EJ, Spaander MC, Veldhuyzen van Zanten SJ.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):79-85.e3. doi: 10.1016/j.cgh.2016.06.029. Epub 2016 Jul 9.

PMID:
27404964
3.

The appropriateness of surveillance colonoscopy intervals after polypectomy.

Schreuders E, Sint Nicolaas J, de Jonge V, van Kooten H, Soo I, Sadowski D, Wong C, van Leerdam ME, Kuipers EJ, Veldhuyzen van Zanten SJ.

Can J Gastroenterol. 2013 Jan;27(1):33-8.

4.

Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.

Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Nauclér EC, Svedberg LE, Nagy P.

J Cardiovasc Pharmacol. 2013 Mar;61(3):250-7. doi: 10.1097/FJC.0b013e31827cb626.

PMID:
23188121
5.

Awareness of postpolypectomy surveillance guidelines: a nationwide survey of colonoscopists in Canada.

van Kooten H, de Jonge V, Schreuders E, Sint Nicolaas J, van Leerdam ME, Kuipers EJ, Veldhuyzen van Zanten SJ.

Can J Gastroenterol. 2012 Feb;26(2):79-84.

6.

Systematic literature review and pooled analyses of risk factors for finding adenomas at surveillance colonoscopy.

de Jonge V, Sint Nicolaas J, van Leerdam ME, Kuipers EJ, Veldhuyzen van Zanten SJ.

Endoscopy. 2011 Jul;43(7):560-72. doi: 10.1055/s-0030-1256306. Epub 2011 Mar 24. Review.

PMID:
21437854
7.

A prospective audit of patient experiences in colonoscopy using the Global Rating Scale: a cohort of 1,187 patients.

de Jonge V, Sint Nicolaas J, Lalor EA, Wong CK, Walters B, Bala A, Kuipers EJ, van Leerdam ME, Veldhuyzen van Zanten SJ.

Can J Gastroenterol. 2010 Oct;24(10):607-13.

8.

Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis.

Sint Nicolaas J, de Jonge V, Steyerberg EW, Kuipers EJ, van Leerdam ME, Veldhuyzen-van Zanten SJ.

Am J Transplant. 2010 Apr;10(4):868-76. doi: 10.1111/j.1600-6143.2010.03049.x. Review.

9.

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P.

JAMA. 2008 Oct 15;300(15):1793-805. doi: 10.1001/jama.300.15.1793. Review. Erratum in: JAMA. 2009 Apr 15;301(15):1544.

PMID:
18854541
10.

Functional dyspepsia: not all roads seem to lead to rome.

van Kerkhoven LA, Laheij RJ, Meineche-Schmidt V, Veldhuyzen-van Zanten SJ, de Wit NJ, Jansen JB.

J Clin Gastroenterol. 2009 Feb;43(2):118-22. doi: 10.1097/MCG.0b013e31815591f7.

PMID:
18719513
11.

Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis.

Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P.

Gut. 2008 Nov;57(11):1545-53. doi: 10.1136/gut.2008.159723. Epub 2008 Aug 1. Review.

PMID:
18676420
12.

Pitfalls in designing trials of functional dyspepsia: the ascent and demise of itopride.

Veldhuyzen Van Zanten SJ.

Gut. 2008 Jun;57(6):723-4. doi: 10.1136/gut.2007.139923. Review. No abstract available.

PMID:
18477673
13.

Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects.

Miwa H, Nakajima K, Yamaguchi K, Fujimoto K, Veldhuyzen VAN Zanten SJ, Kinoshita Y, Adachi K, Kusunoki H, Haruma K.

Aliment Pharmacol Ther. 2007 Jul 15;26(2):257-64.

14.

Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis.

Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ.

J Clin Microbiol. 2006 Nov;44(11):4136-41. Epub 2006 Sep 20.

15.

Canadian consensus on medically acceptable wait times for digestive health care.

Paterson WG, Depew WT, Paré P, Petrunia D, Switzer C, Veldhuyzen van Zanten SJ, Daniels S; Canadian Association of Gastroenterology Wait Time Consensus Group.

Can J Gastroenterol. 2006 Jun;20(6):411-23.

16.

Design of treatment trials for functional gastrointestinal disorders.

Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ.

Gastroenterology. 2006 Apr;130(5):1538-51. Review.

PMID:
16678567
17.

The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy.

Veldhuyzen van Zanten SJ, Thomson AB, Barkun AN, Armstrong D, Chiba N, White RJ, Escobedo S, Sinclair P.

Aliment Pharmacol Ther. 2006 Mar 1;23(5):595-9.

18.

Validation of a symptom diary for patients with gastro-oesophageal reflux disease.

Puhan MA, Guyatt GH, Armstrong D, Wiklund I, Fallone CA, Heels-Ansdell D, Degl'Innocenti A, Veldhuyzen van Zanten SJ, Tanser L, Barkun AN, Chiba N, Austin P, El-Dika S, Schünemann HJ.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):531-41.

19.

Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials.

Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun AN, Thomson AB, Mann V, Escobedo S, Chakraborty B, Nevin K.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):521-9.

20.

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.

Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P.

Am J Gastroenterol. 2005 Jul;100(7):1477-88.

PMID:
15984968
21.

Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool.

Veldhuyzen van Zanten SJ, Bradette M, Chiba N, Armstrong D, Barkun A, Flook N, Thomson A, Bursey F; Canadian Dyspepsia Working Group.

Can J Gastroenterol. 2005 May;19(5):285-303. Review.

PMID:
15915244
22.

Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.

Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, White RJ; CADET-HR Study Group.

Aliment Pharmacol Ther. 2005 May 15;21(10):1189-202.

23.

Review: proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo.

Veldhuyzen Van Zanten SJ.

ACP J Club. 2005 May-Jun;142(3):74. No abstract available.

PMID:
15862073
24.
25.

Use of oesophageal dilatation in clinical practice.

Veldhuyzen van Zanten SJ.

Gut. 2005 Jan;54(1):170. No abstract available.

26.

Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia.

Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ.

Aliment Pharmacol Ther. 2004 Mar 15;19(6):631-41. Review.

27.

Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia.

Chiba N, Veldhuyzen Van Zanten SJ, Escobedo S, Grace E, Lee J, Sinclair P, Barkun A, Armstrong D, Thomson AB.

Aliment Pharmacol Ther. 2004 Feb 1;19(3):349-58.

28.

Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.

Best LM, Haldane DJ, Keelan M, Taylor DE, Thomson AB, Loo V, Fallone CA, Lyn P, Smaill FM, Hunt R, Gaudreau C, Kennedy J, Alfa M, Pelletier R, Veldhuyzen Van Zanten SJ.

Antimicrob Agents Chemother. 2003 Oct;47(10):3138-44.

29.

Development of an interleukin-12-deficient mouse model that is permissive for colonization by a motile KE26695 strain of Helicobacter pylori.

Hoffman PS, Vats N, Hutchison D, Butler J, Chisholm K, Sisson G, Raudonikiene A, Marshall JS, Veldhuyzen van Zanten SJ.

Infect Immun. 2003 May;71(5):2534-41.

30.

A letter from CMAJ's editorial board to the CMA.

Armstrong P, Cashman NR, Cook DJ, Feeny DH, Ghali WA, de Gruijl FR, Hall JG, Herbert CP, Iscoe N, Jadad AR, Kassirer JP, McAlister FA, McGeer AJ, MacMillan HL, Moher D, Phillips S, Redelmeier DA, Schechter MT, Veldhuyzen van Zanten SJ, Yusuf S.

CMAJ. 2002 Nov 26;167(11):1230; author reply 1230-1. English, French. No abstract available.

31.

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme.

Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Veldhuyzen Van Zanten SJ, Burman CF, Lind T, Wrangstadh M, BayerdOrffer E, Lonovics J.

Aliment Pharmacol Ther. 2002 Aug;16(8):1431-42.

32.

Helicobacter pylori eradication reduced the risk for ulcers in dyspeptic patients who were about to begin NSAID treatment.

Veldhuyzen Van Zanten SJ.

ACP J Club. 2002 Jul-Aug;137(1):13. No abstract available.

PMID:
12093212
33.

Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?

Veldhuyzen van Zanten SJ, Talley NJ, Blum AL, Bolling-Sternevald E, Sundin M, Junghard O.

Gut. 2002 May;50 Suppl 4:iv26-30; discussion iv31-2.

34.

Assessment of outcome in dyspepsia: has progress been made?

Veldhuyzen van Zanten SJ.

Gut. 2002 May;50 Suppl 4:iv23-5. Review.

35.

pH-Hp: implications for dyspepsia management.

Axon A, Talley NJ, Veldhuyzen van Zanten SJ.

Gut. 2002 May;50 Suppl 4:iv1. No abstract available.

36.

Treatment of Helicobacter pylori infection unmasks rather than induces symptoms of gastro-oesophageal reflux disease.

Veldhuyzen van Zanten SJ.

Dig Liver Dis. 2001 Nov;33(8):647-8. No abstract available.

PMID:
11785706
37.

The role of psychological functioning in morbid obesity and its treatment with gastroplasty.

Vallis TM, Butler GS, Perey B, Veldhuyzen van Zanten SJ, MacDonald AS, Konok G.

Obes Surg. 2001 Dec;11(6):716-25.

PMID:
11775569
38.

The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia.

Veldhuyzen van Zanten SJ.

Am J Gastroenterol. 2001 Oct;96(10):2811-2. No abstract available.

PMID:
11693312
39.
40.

H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials.

Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ.

Aliment Pharmacol Ther. 2001 Sep;15(9):1291-9.

41.

Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.

Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ.

Am J Gastroenterol. 2001 Mar;96(3):689-96.

PMID:
11280535
42.

The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.

Bardhan K, Bayerdörffer E, Veldhuyzen Van Zanten SJ, Lind T, Mégraud F, Delchier JC, Hellblom M, Stubberöd A, Burman CF, Gromark P, Zeijlon L.

Helicobacter. 2000 Dec;5(4):196-201.

PMID:
11179983
44.

Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group.

Hunt RH, Smaill FM, Fallone CA, Sherman PM, Veldhuyzen van Zanten SJ, Thomson AB.

Can J Gastroenterol. 2000 Nov;14(10):862-8. Review.

PMID:
11111109
45.

Update from the Canadian Dyspepsia Working Group.

Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, Thomson A, Bursey F, Blackshaw P, Frail D, Sinclair P.

CMAJ. 2000 Sep 19;163(6):696. No abstract available.

46.

Concerns about the critical appraisal of the role of H pylori in dyspepsia.

Chiba N, Veldhuyzen van Zanten SJ.

Can Fam Physician. 2000 Sep;46:1732-4. No abstract available.

47.

An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, Thomson A, Bursey F, Blackshaw P, Frail D, Sinclair P.

CMAJ. 2000 Jun 13;162(12 Suppl):S3-23.

48.

Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat.

Peterson TC, Cleary CE, Shaw AM, Malatjalian DA, Veldhuyzen van Zanten SJ.

Dig Dis Sci. 2000 Mar;45(3):466-73.

PMID:
10749319
49.

The urea breath test for Helicobacter pylori infection: taking the wind out of the sails of endoscopy.

Fallone CA, Veldhuyzen van Zanten SJ, Chiba N.

CMAJ. 2000 Feb 8;162(3):371-2. Review. No abstract available.

50.

13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection.

Chiba N, Veldhuyzen Van Zanten SJ.

Can J Gastroenterol. 1999 Oct;13(8):681-3. Review. No abstract available.

PMID:
10545656

Supplemental Content

Loading ...
Support Center